NovaBridge Biosciences(NBP)
$0.90+0.08 (+9.85%)
NBP
NovaBridge Biosciences financials statements
$0.90
At close:+0.08 (+9.85%)
Want to see NBP full AI Analyst Report?
NovaBridge Biosciences (NBP) Ratios
432 Followers
NovaBridge Biosciences Ratios
NBP's free cash flow for Q2 2026 was ¥-16.90M. For the 2026 fiscal year, NBP's free cash flow was decreased by ¥-493.24K and operating cash flow was ¥-16.40M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.09 | 20.90 | 5.67 | 5.50 | 7.66 |
| Quick Ratio | 8.09 | 20.90 | 5.60 | 5.62 | 7.66 |
| Cash Ratio | 7.83 | 8.07 | 5.20 | 4.87 | 5.65 |
| Solvency Ratio | -1.36 | -1.91 | -1.63 | -2.35 | -2.23 |
| Operating Cash Flow Ratio | -0.77 | -6.23 | -0.18 | -1.67 | -1.56 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -2.43 | -401.38 | 0.00 |
| Net Current Asset Value | ¥ 187.94M | ¥ 1.21B | ¥ 1.44B | ¥ 2.56B | ¥ 3.74B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.02 | 0.05 | 0.01 | 0.02 |
| Debt-to-Equity Ratio | 0.01 | 0.02 | 0.08 | 0.01 | 0.02 |
| Debt-to-Capital Ratio | 0.01 | 0.02 | 0.07 | 0.01 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.03 | 0.00 | 0.02 |
| Financial Leverage Ratio | 1.13 | 1.06 | 1.52 | 1.35 | 1.23 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 30.42 | -18.90 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | -5018.58 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.03 | 0.35 | 1.61 | 0.46 | 1.48 |
| Net Debt to EBITDA | 2.35 | 1.26 | 5.83 | 61.99 | 1.66 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 100.00% | 2325.83% | 47.25% |
| EBIT Margin | 0.00% | 0.00% | -7749.35% | 492.14% | -2353.06% |
| EBITDA Margin | 0.00% | 0.00% | -7674.20% | 478.91% | -2337.41% |
| Operating Profit Margin | 0.00% | 0.00% | -11395.09% | 3422.17% | -2353.06% |
| Pretax Profit Margin | 0.00% | 0.00% | -32674.02% | 9097.35% | -2649.26% |
| Net Profit Margin | 0.00% | 0.00% | -32674.02% | 23438.90% | -2648.70% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -4609.38% | 23438.90% | -2648.70% |
| Net Income Per EBT | 52.38% | 44.73% | 100.00% | 257.65% | 99.98% |
| EBT Per EBIT | 93.71% | 96.64% | 286.74% | 265.84% | 112.59% |
| Return on Assets (ROA) | -17.76% | -10.45% | -56.09% | -61.55% | -41.42% |
| Return on Equity (ROE) | -20.03% | -11.05% | -85.31% | -83.35% | -50.82% |
| Return on Capital Employed (ROCE) | -40.35% | -25.18% | -23.22% | -10.72% | -41.38% |
| Return on Invested Capital (ROIC) | -40.20% | -25.08% | -3.20% | -10.70% | -41.12% |
| Return on Tangible Assets | -17.76% | -10.45% | -56.45% | -66.12% | -43.60% |
| Earnings Yield | -11.78% | -32.21% | -130.65% | -105.40% | -10.20% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 2.45 | -2.22 | 1.44 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -0.34 | 10.87 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.81 | -0.09 | 0.56 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | -0.00 | 0.02 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | -0.00 | 0.02 |
| Cash Conversion Cycle | 0.00 | 0.00 | 149.15 | -1239.97 | 286.33 |
| Days of Sales Outstanding | 0.00 | 0.00 | 149.15 | -164.17 | 252.74 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | -1075.80 | 33.59 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 149.15 | -1239.97 | 286.33 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.21 | -4.74 | -0.88 | -13.36 | -12.82 |
| Free Cash Flow Per Share | -0.21 | -4.74 | -0.88 | -13.92 | -13.21 |
| Dividend Paid and CapEx Coverage Ratio | -2942.43 | -1097.27 | -443.27 | -24.06 | -32.51 |
| Capital Expenditure Coverage Ratio | -2942.43 | -1097.27 | -443.27 | -24.06 | -32.51 |
| Operating Cash Flow Coverage Ratio | -6.72 | -13.57 | -0.54 | -28.80 | -8.65 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -16.24 | 103.09 | -11.05 |
| Free Cash Flow Yield | -5.24% | -76.39% | -6.51% | -48.28% | -4.39% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -8.65 | -1.39 | -0.77 | -0.95 | -9.80 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 250.09 | -222.39 | 259.67 |
| Price-to-Book (P/B) Ratio | 1.70 | 0.34 | 0.65 | 0.79 | 4.98 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -19.07 | -1.31 | -15.36 | -2.07 | -22.79 |
| Price-to-Operating Cash Flow Ratio | -19.07 | -1.31 | -15.40 | -2.16 | -23.49 |
| Price-to-Earnings Growth (PEG) Ratio | 0.10 | 0.02 | 0.02 | 0.90 | 0.02 |
| Enterprise Value Multiple | -2.10 | -0.09 | 2.57 | 15.55 | -9.45 |
| Enterprise Value | 185.30M | 33.77M | -885.73M | -796.75M | 19.45B |
| EV to EBITDA | -2.10 | -0.09 | 2.57 | 15.55 | -9.45 |
| EV to Sales | 0.00 | 0.00 | -197.45 | 74.48 | 220.92 |
| EV to Free Cash Flow | -8.99 | -0.09 | 12.13 | 0.69 | -19.39 |
| EV to Operating Cash Flow | -9.00 | -0.09 | 12.16 | 0.72 | -19.98 |
| Tangible Book Value Per Share | 2.34 | 18.08 | 20.45 | 33.05 | 56.70 |
| Shareholders’ Equity Per Share | 2.34 | 18.08 | 20.65 | 36.46 | 60.42 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.86 | -0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.05 | -0.13 | 1.16 |
| Net Income Per Share | -0.47 | -2.00 | -17.62 | -30.39 | -30.70 |
| Tax Burden | 0.52 | 0.45 | 1.00 | 2.58 | 1.00 |
| Interest Burden | 0.94 | 0.97 | 4.22 | 18.49 | 1.13 |
| Research & Development to Revenue | 0.00 | 0.00 | 25.49 | -14.54 | 2.16 |
| SG&A to Revenue | 0.00 | 0.00 | 14.25 | -76.26 | 10.22 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 2.29 | -33.39 | 6.91 |
| Income Quality | 0.23 | 1.06 | 0.35 | 0.44 | 0.42 |
Currency in CNY

